Please wait a minute...
文章检索
预防医学  2019, Vol. 31 Issue (9): 882-885    DOI: 10.19485/j.cnki.issn2096-5087.2019.09.005
  论著 本期目录 | 过刊浏览 | 高级检索 |
激素治疗干预对围绝经期女性乳腺病变的影响
马林1, 黄坚1, 陈临节1, 楼向明1, 周健2, 夏建余2, 陆晨蕾3, 吴红艳4, 张治芬1
1.杭州市妇产科医院妇科,浙江 杭州 310008;
2.杭州市肿瘤医院;
3.浙江中医药大学;
4.南京医科大学附属杭州医院
Menopausal hormone therapy on breast lesions in perimenopausal women
MA Lin*, HUANG Jian, CHEN Lin-jie, LOU Xiang-ming, ZHOU Jian, XIA Jian-yu, LU Chen-lei, WU Hong-yan
ZHANG Zhi-fen*Department of Gynecology,Hangzhou Women's Hospital,Hangzhou,Zhejiang 310008,China
全文: PDF(490 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 分析激素治疗(MHT)干预对围绝经期女性乳腺病变的影响,为围绝经期女性改善MHT干预效果提供依据。方法 选取杭州市妇产科医院就诊的40~60岁围绝经期综合征患者为研究对象,接受MHT干预的患者纳入干预组,并根据MHT干预方案分为雌孕激素周期治疗组(A组)、雌孕激素连续联合治疗组(B组)和单雌激素治疗组(C组);未干预患者为对照组。所有患者定期接受乳腺钼靶检查,采用广义估计方程分析干预组与对照组乳腺病变情况。结果 干预组80例,其中A组49例、B组26例、C组5例;对照组80例。经过2年随访,干预组与对照组的乳腺密度、乳腺纤维组织容积、乳房容积干预前后差异、组间差异及组间与时间交互作用均无统计学意义(P>0.05);干预组与对照组的乳房钙化检出率和乳房肿块检出率干预前后差异有统计学意义(P<0.05),组间差异及组间与时间交互作用均无统计学意义(P>0.05)。结论 未发现围绝经期女性的乳腺病变风险与MHT干预有关。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
马林
黄坚
陈临节
楼向明
周健
夏建余
陆晨蕾
吴红艳
张治芬
关键词 围绝经期绝经激素治疗乳腺密度乳房钙化乳腺纤维组织容积    
AbstractObjective To explore the correlation between menopausal hormone therapy(MHT)and breast lesions in perimenopausal women,and to provide evidence for safe use of MHT. Methods The 40-60 year-old women who visited Hangzhou Women's Hospital and met the diagnostic criteria for perimenopausal syndrome were recruited. The intervention group received MHT and was divided into three subgroups according to the MHT regimen:estrogen-progesterone cycle therapy(A),estrogen-progesterone continuous therapy(B),estrogen therapy(C). The control group did not receive MHT. All the patients received regular mammography to quantify and evaluate breast lesions. The generalized estimating equation was used to analyze the changes of breast lesions between different groups. Results There were 80 cases in the intervention group,with 49 in group A,26 in group B,5 in group C,and 80 cases in the control group. After two years of follow-up,there was no statistically significant differences of time,group and interaction in breast density,volume of breast fibrous tissue and the volume of breast between three intervention groups and the control group(P>0.05); there was no statistically significant differences of group and interaction in positive rate of calcification and breast mass between the intervention group and the control group(P>0.05). Conclusion Receiving MHT intervention for two years did not increase the risk of breast lesions.
Key wordsPeri-menopause    Menopausal hormone therapy    Breast density    Breast calcification    Breast fibrous tissue volume
收稿日期: 2019-04-27      出版日期: 2019-09-02
ZTFLH:  R458.7  
基金资助:浙江省科技计划项目(2017C33203); 杭州市科技发展计划项目(20140733Q16)
通信作者: 黄坚,E-mail:huangjian96e90@163.com   
作者简介: 马林,硕士,主治医师,主要从事妇科内分泌疾病诊治工作
引用本文:   
马林, 黄坚, 陈临节, 楼向明, 周健, 夏建余, 陆晨蕾, 吴红艳, 张治芬. 激素治疗干预对围绝经期女性乳腺病变的影响[J]. 预防医学, 2019, 31(9): 882-885.
MA Lin, HUANG Jian, CHEN Lin-jie, LOU Xiang-ming, ZHOU Jian, XIA Jian-yu, LU Chen-lei, WU Hong-yan. Menopausal hormone therapy on breast lesions in perimenopausal women. Preventive Medicine, 2019, 31(9): 882-885.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2019.09.005      或      http://www.zjyfyxzz.com/CN/Y2019/V31/I9/882
[1] 中华医学会妇产科学分会绝经学组.中国绝经管理与绝经激素治疗指南(2018)[J]. 协和医学杂志,2018,9(6):19-32.
[2] 胡颖敏,蓝坚华,王佩英,等. 女性围绝经期综合征危险因素分析[J]. 预防医学,2017,29(10):1051-1057.
[3] 中华医学会妇产科学分会绝经学组. 绝经相关激素补充治疗的规范诊疗流程[J]. 中华妇产科杂志,2013,48(2):155-158.
[4] THORLEY J.HRT for menopause:a delicate balance[J]. Lancet Diabetes Endocrinol,2016,4:25.
[5] HOLM J,HUMPHREYS K,LI J,et al.Risk factors and tumor characteristics of interval cancers by mammographic density[J]. J Clin Oncol,2015,33(9):1030-1037.
[6] DAYE D,KELLER B,CONANT E F,et al.Mammographic parenchymal patterns as an imaging marker of endogenous hormonal exposure:a preliminary study in a high-risk population[J]. Acad Radiol,2013,20(5):635-646.
[7] DAVEY D A.Menopausal hormone therapy:a better and safer future[J]. Climacteric,2018,21(5):454-461.
[8] SEIFERT-KLAUS V,KINGSWELLS E,HITCHCOCK C L,et al.Estrogen and progestogen use in peri- and postmenopausal women:March 2007 position statement of The North American Menopause Society[J]. Menopause,2008,15(1):203-206.
[9] PINES A.Hormone therapy and breast cancer:the press-release version of WHI study data[J]. Climacteric,2013,16(2):222-225.
[10] WOOLCOTT C G,CONROY S M,NAGATA C,et al.Methods for assessing and representing mammographic density:an analysis of 4 case-control studies[J]. Am J Epidemiol,2014,179(2):236-244.
[11] 张洁琼,张琴,孟莉. 激素替代治疗与乳腺癌发生风险概述[J].中国妇幼保健,2015,30(36):6669-6672.
[12] STERNS E E,ZEE B.Mammographie density changes in perimenopausal and postmenopausal women is effect of hormone replacement therapy predietable[J]. Breast Cancer Res Treat,2000,59(2):125-132.
[13] 张巧利,李芬,吕淑兰,等. 性激素补充治疗对妇女乳腺密度的影响[J].现代妇产科进展,2014,23(12):994-997.
[14] MCTIERNAN A,MARTIN CF,PECK JD,et al.Estrogen- plus-progestin use and mammographic density in postmenopausal women:Women's Health Initiative randomized trial[J]. J Natl Cancer Inst,2005,97(18):1366-1376.
[15] SENDAG F,COSAN-TEREK M,OZSENER S,et al.Mammographic density changes during different postmenopausal hormone replacement therapies[J]. Fertil Steril,2001,76(3):445-450.
[16] MARTIN L J,MINKINS S,BOYD N F.Hormone therapy,mammographic density,and breast cancer risk[J]. Maturities,2009, 64(1):20-26.
[17] KOTSOPOULSO J,GRONWALD J,KALAN B Y,et al.Hormone replacement therapy after oophorectomy and breast cancer risk among BRCAI mutation carriers[J]. JAMA Oncol,2018,4(8):1059-1065.
[18] STUTE P,WILDT L,NEULEN J.The impact of micronized progesterone on breast cancer risk:a systematic review[J]. Climacteric,2018,21(2):111-122.
No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed